May 20, 2021
May 20, 2021 – The U.S. FDA has approved an expanded indication for Kedrab® [rabies immune globulin
(human)] solution for wound infiltration and intramuscular
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health
May 20, 2021
May 20, 2021 – The U.S. FDA has approved a new indication for Opdivo® (nivolumab), manufactured by
Bristol Myers Squibb
May 13, 2021
May 13, 2021 – The U.S. FDA has approved Heron Therapeutics’ ZynrelefTM (bupivacaine/meloxicam)
extended-release solution for soft tissue or periarticular instillation to produce postsurgical
May 7, 2021
May 7, 2021 - As your Prescription Benefit Facilitator, Global Reach Health is committed to creating value by providing the highest quality service, innovative clinical solutions, and valuable trend management strategies.
May 7, 2021
May 7, 2021 – NovoNordisk has voluntarily recalled 1,468 samples of the following insulin products:
Levemir®, Tresiba®, Fiasp®, Novolog®, and Xultophy®. The affected samples were stored
May 6, 2021
May 6, 2021 – The U.S. FDA has approved a new single-dose option for Injectafer® (ferric carboxymaltose
injection), manufactured by Daiichi Sankyo. Injectafer is indicated to treat iron deficiency
May 5, 2021
May 5, 2021 – The U.S. FDA has approved a new indication for Keytruda® (pembrolizumab), manufactured
by Merck. Keytruda is now indicated for use in combination with trastuzumab and
May 4, 2021
May 4, 2021 – Hospira, Inc., a subsidiary of Pfizer, has voluntarily recalled one lot of 0.5% Bupivacaine
Hydrochloride (HCl) Injection, USP 30mL, and one lot of 1% Lidocaine HCl Injection